XXXXXXXXXXXXXXXXXX

XX/XX/XXXX XX/XX/XXXX XX/XX/XXXX

XXXXXXXX

XXXXXXXX 25

XXXXXXXXXXXXX

XX/XX/XXXX

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

XXXXXXXXXXXXXXXXXX

25

Lower

Lower RiskRelatively lower risk of lung cancer. Consistent with REVEAL scores in a clinical study where 94% of the subjects with a score of 49 or less had benign disease (1). REVEAL is a risk assessment tool, which is to be used only in conjunction with standard clinical assessments. The test is not intended as a screening or stand-alone diagnostic assay.

The REVEAL Lung Nodule Characterization test is based on a multianalyte assay with an algorithmic analysis that is proprietary to MagArray, Inc. The test uses immunoassay, microarray, and magnetic nanoparticle detection techniques to obtain laboratory data for analysis and calculation of the resulting risk score of lung cancer. Please visit www.magarray.com for more information.

The performance characteristics of this test were validated by MagArray, Inc. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. MagArray, Inc. is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.Test performed at MagArray, Inc.

MagArray, Inc. CLIA ID#: 05D2135449 MagArray Document: CR0016-ART–3.0P

MagArray, Inc, 521 Cottonwood Dr., Ste. 121, Milpitas, CA 95035 • Phone (408) 753-6429; Fax (844) 825-7635 • Laboratory Director:Alan Wu, Ph.D., DABCC

1. Trivedi et al, Biomedical Research and Clinical Practice, 2018. 2. Trivedi et al, Biomedical Research and Reviews, 2018.

XXXXXXXXXXXXXXXXXX

XX/XX/XXXX XX/XX/XXXX XX/XX/XXXX

XXXXXXXX

XXXXXXXX 75

XXXXXXXXXXXXX

XX/XX/XXXX

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

XXXXXXXXXXXXXXXXXX

75

Higher

Higher RiskRelatively higher score, consistent with REVEAL scores for subjects in a clinical study (1). Based on that study, subjects with a score of 50 or higher had a relatively higher risk of having lung cancer. REVEAL is a risk assessment tool, which is to be used only in conjunction with standard clinical assessments. The test is not intended as a screening or stand-alone diagnostic assay.

The REVEAL Lung Nodule Characterization test is based on a multianalyte assay with an algorithmic analysis that is proprietary to MagArray, Inc. The test uses immunoassay, microarray, and magnetic nanoparticle detection techniques to obtain laboratory data for analysis and calculation of the resulting risk score of lung cancer. Please visit www.magarray.com for more information.

The performance characteristics of this test were validated by MagArray, Inc. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. MagArray, Inc. is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.Test performed at MagArray, Inc.

MagArray, Inc. CLIA ID#: 05D2135449 MagArray Document: CR0016-ART–3.0P

MagArray, Inc, 521 Cottonwood Dr., Ste. 121, Milpitas, CA 95035 • Phone (408) 753-6429; Fax (844) 825-7635 • Laboratory Director:Alan Wu, Ph.D., DABCC

1. Trivedi et al, Biomedical Research and Clinical Practice, 2018. 2. Trivedi et al, Biomedical Research and Reviews, 2018.